HIGHLIGHTS
- who: Jan-Niklas Eckardt from the Data set and definitions We retrospectively analyzed a cohort of , adult AML patients that were treated in previously reported multicenter trials (AML96(ref[34]) [NCT00180115], AML2003(ref. [35]) [NCT00180102], + (ref. [36]) [NCT, ], and SORAML(ref. [37]) [NCT00893373]) or registered in the bio-registry of the German Study Alliance Leukemia (SAL [NCT03188874]) which encompasses , centers specialized in the treatment of hematologic neoplasms across Germany and the Czech Republic. Patients were eligible based on diagnosis of AML according to WHO criteria [1], age u2265 , years, curative treatment intent and available biomaterial at diagnosis . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.